We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Molecular Devices

Molecular Devices provides innovative bioanalytical solutions for protein and cell biology in life science research, ... read more Featured Products: More products

Download Mobile App




Immunoassay Evaluated for Quantitative Measurement of Fecal α1-Antitrypsin

By LabMedica International staff writers
Posted on 09 Aug 2016
The measurement of the protease α1-antitrypsin (A1A) in stool specimens can be used to detect the presence of serum proteins in the gastrointestinal tract a sign of protein-losing enteropathy (PLE).

The major causes of PLE can be divided into erosive and non-erosive gastrointestinal disorders, as well as increased central venous pressure or mesenteric lymphatic obstruction and among such disorders are enteritis, Crohn disease, ulcerative colitis, and celiac disease.

Scientists at the Associated Regional and University Pathologists (ARUP) Laboratories (Salt Lake City, UT, USA) used residual stool specimens sent to ARUP laboratories for fecal A1A testing, as well as paired sera and timed stool samples obtained from healthy volunteers. More...
A1A in stool was measured with a polyclonal antibody-based enzyme-linked immunosorbent assay (ELISA). Assay imprecision, analytical sensitivity, linearity, accuracy, analyte stability, and reference intervals were determined.

Stool A1A was measured by using the Human α1-Antitrypsin ELISA (ImmuChrom, Heppenheim, Germany). This assay is a polyclonal immunometric method used for quantifying the A1A extracted from stool. Signals for ELISA plates were quantified with a SPECTRAmax PLUS plate reader (Molecular Devices LLC, Sunnyvale, CA, USA). Reference intervals for stool A1A and A1A clearance were established using timed stool samples and sera collected from 124 healthy volunteers (62 males, 62 females; ages 19–61 years).

The investigators found that the limit of quantification of the ELISA method used was 2.0 ng/mL, and the assay was linear to 85 ng/mL. The mean recovery of A1A added to samples was 108.2% and A1A was stable in stool for a minimum of two days, seven days, and three months at room temperature, 4 °C to 8 °C and −20 °C, respectively. The upper 95th percentile reference limits for A1A in stool and A1A clearance were 0.48 mg/g and 49 mL/day, respectively.

The authors concluded that the ImmuChrom human A1A ELISA demonstrates acceptable performance characteristics for quantifying A1A in stool extracts. Furthermore, this stool ELISA may be used in combination with the Tina-Quant A1A serum assay (Roche Diagnostics, Basel Switzerland) to assess A1A clearance for diagnosing and monitoring PLE. The study was published in the July 2016 issue of the Journal of Applied Laboratory Medicine.

Related Links:
Associated Regional and University Pathologists Laboratories
ImmuChrom
Molecular Devices
Roche Diagnostics

New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Portable Electronic Pipette
Mini 96
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The genomic test measures eight gene activities in a melanoma tumor and combines this data with patient factors like age and tumor thickness (Photo courtesy of 123RF)

Genomic Test Could Reduce Lymph Node Biopsy Surgery in Melanoma Patients

Accurately determining whether melanoma has spread to the lymph nodes is crucial for guiding treatment decisions, yet the standard procedure—sentinel lymph node biopsy—remains invasive, costly, and unnecessary... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.